A new MRI contrast agent may provide a viable non-invasive alternative for the detection of interstitial cystitis, according to preliminary research presented at the 5th International Consultation on Interstitial Cystitis Japan (ICICJ) in Kyoto, Japan.
Through intravesical contrast-enhanced MRI (ICE-MRI), the dual-component MRI contrast agent LP-20 facilitated enhanced phenotyping differentiation between bladder-centric interstitial cystitis (IC) and endometriosis, according to preliminary research presented at the 5th International Consultation on Interstitial Cystitis Japan (ICICJ) in Kyoto, Japan.
Researchers found that T1- and T2-weighted ICE-MRI images with LP-20 (Lipella Pharmaceuticals) enabled a wider field of view for pelvic abnormalities as well as visualization of sub-surface lesion depth and wall thickening on the serosal side of the bladder that one cannot see via cystoscopy.
Designed for interstitial cystitis detection, the LP-20 agent may also facilitate the diagnosis of bladder pain syndrome (BPS), according to Lipella Pharmaceuticals.
“LP-20 provides a valuable tool for phenotyping IC/BPS, potentially streamlining patient identification for clinical trials and improving timely access to effective treatments,” added lead study author Pradeep Tyagi, M.D., an associate professor in the Department of Urology at the University of Pittsburgh Medical Center.
The company added that LP-20, which has been the subject of completed pre-clinical and proof-of-concept human trial research, can also diagnose the progression of bladder cancer to muscle invasive bladder cancer.
References
1. Chancellor M, Moon CH, Chermansky C, Yoshimura N, Kaufman J, Tyagi P. Size-dependent paracellular diffusion into urothelium is embodied by intravesical contrast enhanced magnetic resonance imaging (ICE-MRI). Presented at the 5th International Consultation on Interstitial Cystitis Japan (ICICJ), August 21-23, Kyoto, Japan.
2. Lipella Pharmaceuticals. Lipella Pharmaceuticals unveils advanced bladder imaging technique at ICICJ conference. BioSpace. Available at https://www.biospace.com/lipella-pharmaceuticals-unveils-advanced-bladder-imaging-technique-at-icicj-conference . Published August 21, 2024. Accessed August 21, 2024.
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.